These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 35443802)

  • 21. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
    Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
    Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of Relevant Factors of Refractory and Relapse DLBCL Treated by Rituximab Combined with CHOP/EPOCH Regimen].
    Zhang J; Gu Y; Wu X; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1912-1918. PubMed ID: 33283719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.
    Dürig J; Uhlig J; Gerhardt A; Ritter M; Hapke G; Heßling J; Staib P; Wolff F; Krumm K; von Weikersthal LF
    Cancer Med; 2023 Feb; 12(3):2739-2751. PubMed ID: 36017743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
    Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
    J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody and immunotherapy in diffuse large B-cell lymphoma.
    Barraclough A; Hawkes EA
    Semin Hematol; 2023 Nov; 60(5):338-345. PubMed ID: 38072722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line treatment of diffuse large B-cell lymphoma: Evolution of options.
    Fabbri N; Mussetti A; Sureda A
    Semin Hematol; 2023 Nov; 60(5):305-312. PubMed ID: 38342663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
    Witzens-Harig M; Memmer ML; Dreyling M; Hess G
    BMC Cancer; 2013 Jun; 13():308. PubMed ID: 23799873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
    de Jong MRW; Visser L; Huls G; Diepstra A; van Vugt M; Ammatuna E; van Rijn RS; Vellenga E; van den Berg A; Fehrmann RSN; van Meerten T
    PLoS One; 2018; 13(2):e0193098. PubMed ID: 29489886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
    J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of combinatorial antibody therapies for diffuse large B cell lymphoma.
    Geanes ES; Krepel SA; McLennan R; Pierce S; Khanal S; Bradley T
    Front Med (Lausanne); 2022; 9():1034594. PubMed ID: 36353222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
    Topp MS; Eradat H; Florschütz A; Hochhaus A; Wrobel T; Walewski J; Knopinska-Posluszny W; Kanate AS; Lech-Maranda E; Brunnberg U; Chitra S; Nielsen TG; Sellam G; Shivhare M; Lossos IS
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):811-817. PubMed ID: 35182224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma.
    Yoon DH; Koh Y; Jung M; Kwak JE; Shin EC; Hwang YK; Kim WS
    Transplant Cell Ther; 2023 Apr; 29(4):253.e1-253.e9. PubMed ID: 36610490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.
    Wang S; Wang L; Hu J; Qian W; Zhang X; Hu Y; Zhu Q; Chen B; Wu D; Chang CH; Xu P; Zheng X; Wei J; Liu Y; Cui G; Tang Y; Ma Y; Huang H; Yi H; Zhao W
    Cancer Commun (Lond); 2021 Mar; 41(3):229-239. PubMed ID: 33482051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
    Kawasaki N; Nishito Y; Yoshimura Y; Yoshiura S
    Br J Haematol; 2022 Oct; 199(2):245-255. PubMed ID: 35764309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.